Additional monitoring: black triangle medicines
Additional monitoring marks medicines that authorities watch more closely, shown by a black inverted triangle in the SmPC and the package leaflet.
Also known as: black triangle, inverted black triangle, black symbol
4 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Legal basis
- Article 23 of Regulation (EC) No 726/2004; Implementing Regulation (EU) No 198/2013
- Symbol
- Inverted black triangle in the SmPC and package leaflet, not on the outer packaging
- Always applies to
- New active substances and biologicals authorised after 1 January 2011, conditional and exceptional authorisations, and medicines with required studies
- Duration
- Five years, or until the PRAC removes the medicine from the list
How it works
Article 23 of Regulation (EC) No 726/2004, introduced by the 2010 pharmacovigilance legislation, requires EMA to set up and publish a list of medicinal products subject to additional monitoring. Being on the list does not mean that a medicine is unsafe. It means that less is known about it than about established medicines, or that data on long-term use are limited, so authorities want suspected adverse reactions reported with particular care. The list covers centrally and nationally authorised medicines, is reviewed every month by the PRAC, and is published by EMA and by the national authorities. GVP Module X explains how it operates.
Additional monitoring always applies to a medicine that contains a new active substance authorised in the EU after 1 January 2011, to biological medicines authorised after that date, including biosimilars, to medicines with a conditional marketing authorisation or one granted under exceptional circumstances, and to medicines whose holder is required to carry out additional studies, for instance an imposed post-authorisation safety study. Other medicines subject to specific conditions can be added after consultation of the PRAC, at the request of the Commission for centrally authorised products or of a national authority for others. A medicine can be listed when it is first authorised or at any later point in its life. It stays on the list for five years or until the PRAC decides to remove it; a medicine listed because of a condition is removed once the condition has been fulfilled.
Listing changes the product information. Commission Implementing Regulation (EU) No 198/2013 selected the symbol, an inverted equilateral black triangle, sized in proportion to the text that follows it. It appears in the SmPC and the package leaflet together with the statement that the medicinal product is subject to additional monitoring and a standard sentence asking healthcare professionals, or in the leaflet patients, to report suspected adverse reactions. The wording is fixed in the QRD template. The symbol does not appear on the outer packaging or the labelling. Authorisations granted before 1 September 2013 had to add it by 31 December 2013; since then it has been part of the product information from first approval. GVP Module X also expects holders to make the status clear in material they distribute to healthcare professionals and patients.
What goes wrong
The triangle and statement left out of a national text when a product is added to the list after authorisation, or left in after it has been removed; a biosimilar holder not noticing that its product is listed in its own right as a biological medicine authorised after 1 January 2011; leaflet stock printed with the old text during the changeover; the symbol reproduced too small, or added to the carton where it does not belong; and no variation filed to delete the statement after removal from the list. Because the list is reviewed monthly, the check has to recur, not happen once at approval.
Timing
At authorisation
A medicine in the mandatory scope is listed and carries the triangle and statement from its first approved product information.
Every month
The PRAC reviews the list and EMA publishes the update.
Five years, or condition fulfilled
The medicine is removed from the list.
After a change of status
The holder varies the SmPC and package leaflet to add or delete the symbol and statement.
The PRAC reviews the list every month and EMA publishes the updated version. A medicine stays listed for five years or until the PRAC decides to remove it, and one listed because of a condition stays until the condition is fulfilled. When a medicine is added or removed after authorisation, the holder updates the SmPC and the package leaflet through a variation.
Additional monitoring: common questions
What does the black triangle on a medicine mean?
The inverted black triangle shows that the medicine is on the EU list of medicines under additional monitoring. It does not mean the medicine is unsafe. It tells healthcare professionals and patients that regulators want suspected adverse reactions reported, usually because the medicine is new or long-term data are limited. The symbol appears in the SmPC and the package leaflet, not on the outer packaging.
Which medicines are under additional monitoring?
Always: medicines containing a new active substance authorised in the EU after 1 January 2011, biological medicines authorised after that date, medicines with a conditional authorisation or one granted under exceptional circumstances, and medicines whose holder must carry out additional studies. Other medicines subject to specific conditions can be added after consultation of the PRAC. EMA publishes the list, and the PRAC reviews it every month.
How long does a medicine stay under additional monitoring?
Five years, or until the PRAC decides to remove it from the list. Under Article 23 of Regulation (EC) No 726/2004 a medicine listed because of a condition, such as an imposed study, is removed once the condition has been fulfilled. After removal the holder files a variation to delete the black triangle and the accompanying statement from the SmPC and package leaflet.